CLOBEVATE SUMMARY
Clobevate® (Clobetasol Propionate Gel) contains the active compound clobetasol propionate, a synthetic corticosteroid, for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.
Clobevate is a super-high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in children under 12 years of age is not recommended.
|
NEWS HIGHLIGHTSMedia Articles Related to Clobevate (Clobetasol Topical)
EU Approves Dupilumab (Dupixent) for Atopic Dermatitis Source: Medscape Allergy & Clinical Immunology Headlines [2017.09.28] The European Commission has granted marketing authorization to dupilumab for adults with moderate to severe atopic dermatitis, according to a company news release. International Approvals
Atopic Eczema (Atopic Dermatitis) Quiz: Test Your Skin Disorders IQ Source: MedicineNet Atopic Dermatitis Specialty [2017.09.20] Title: Atopic Eczema (Atopic Dermatitis) Quiz: Test Your Skin Disorders IQ Category: MedicineNet Quiz Created: 3/20/2012 12:50:00 PM Last Editorial Review: 9/20/2017 12:22:53 PM
Seborrheic Dermatitis Source: MedicineNet Eye Care Specialty [2017.08.09] Title: Seborrheic Dermatitis Category: Diseases and Conditions Created: 3/16/2012 12:00:00 AM Last Editorial Review: 8/9/2017 12:00:00 AM
Contact Dermatitis Source: MedicineNet hydrocortisone valerate Specialty [2017.06.09] Title: Contact Dermatitis Category: Symptoms and Signs Created: 4/1/2014 12:00:00 AM Last Editorial Review: 6/9/2017 12:00:00 AM
Atopic Dermatitis Source: MedicineNet betamethasone dipropionate Specialty [2016.12.21] Title: Atopic Dermatitis Category: Diseases and Conditions Created: 12/31/1997 12:00:00 AM Last Editorial Review: 12/21/2016 12:00:00 AM
Published Studies Related to Clobevate (Clobetasol Topical)
Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in
children: a randomized clinical trial. [2014] IMPORTANCE: Alopecia areata is an idiopathic cause of hair loss with limited
therapeutic repertoire. OBJECTIVE: To compare the efficacy and safety of a high- vs low-potency topical
corticosteroid in pediatric patients...
A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05%
clobetasol propionate ointment in discoid lupus erythematosus by modified
cutaneous lupus erythematosus disease area and severity index. [2012] CONCLUSION: The present study proved the efficacy of twice-daily tacrolimus and
A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0.1% vs. clobetasol propionate 0.05% in childhood vitiligo. [2011.09] BACKGROUND: Both clobetasol propionate 0.05% (CP 0.05%) and tacrolimus 0.1% (T 0.1%) ointments have been shown to be efficacious and safe in treating vitiligo in the paediatric population. OBJECTIVES: To assess efficacy and safety of these two therapies compared with each other and with placebo... CONCLUSIONS: Both CP 0.05% and T 0.1% ointments offer similar benefit in paediatric vitiligo, both facial and nonfacial. The facial lesions responded faster than the nonfacial ones. (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists.
Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis. [2011.08] AIM: Palmoplantar psoriasis (PPP) produces significant morbidity and requires prompt treatment. Topical agents form the mainstay of therapy. We compared the efficacy and side-effect profile of a steroid/coal-tar combination with topical psoralen and solar ultraviolet A (PUVAsol) in PPP... CONCLUSION: Both treatments had comparable efficacy. In both groups, patients experienced 'good improvement' after 16 weeks of therapy. (c) The Author(s). CED (c) 2011 British Association of Dermatologists.
Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0.05% combined with ketoconazole shampoo 2%: a randomized, controlled study. [2011.07] BACKGROUND: Topical antifungals and corticosteroids are the mainstay of treatment for seborrhoeic dermatitis. The short-contact clobetasol propionate 0.05% shampoo (CP) is an efficacious and safe once-daily treatment for scalp psoriasis. OBJECTIVES: To evaluate the efficacy and safety of CP alone and combined with ketoconazole shampoo 2% (KC) in the treatment of moderate to severe scalp seborrhoeic dermatitis... CONCLUSIONS: The combination therapy of twice-weekly CP alternating with twice-weekly KC provided significantly greater efficacy than KC alone and a sustained effect in the treatment of moderate to severe scalp seborrhoeic dermatitis. (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists 2011.
|